Is FBIO or VSTM more profitable?

Fortress Biotech has a net margin of 193.12% compared to Verastem's net margin of -391.17%. Fortress Biotech's return on equity of 109.66% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Fortress Biotech 193.12% 109.66% 45.56% Verastem -391.17% -486.40% -91.56%

Does the media refer more to FBIO or VSTM?

In the previous week, Verastem had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 4 mentions for Verastem and 2 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 1.32 beat Verastem's score of 0.89 indicating that Fortress Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verastem 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VNDA or FBIO?

In the previous week, Vanda Pharmaceuticals had 4 more articles in the media than Fortress Biotech. MarketBeat recorded 6 mentions for Vanda Pharmaceuticals and 2 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 1.32 beat Vanda Pharmaceuticals' score of 0.74 indicating that Fortress Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortress Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SABS or FBIO?

In the previous week, SAB Biotherapeutics had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 3 mentions for SAB Biotherapeutics and 2 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 1.32 beat SAB Biotherapeutics' score of 0.70 indicating that Fortress Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SAB Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortress Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CDXS or FBIO?

In the previous week, Codexis and Codexis both had 2 articles in the media. Fortress Biotech's average media sentiment score of 1.32 beat Codexis' score of 0.93 indicating that Fortress Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortress Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AGEN or FBIO more profitable?

Fortress Biotech has a net margin of 193.12% compared to Agenus' net margin of 50.49%. Fortress Biotech's return on equity of 109.66% beat Agenus' return on equity. Company Net Margins Return on Equity Return on Assets Agenus 50.49% -31.66% 42.71% Fortress Biotech 193.12% 109.66% 45.56%

Does the media favor AGEN or FBIO?

In the previous week, Agenus had 22 more articles in the media than Fortress Biotech. MarketBeat recorded 24 mentions for Agenus and 2 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 1.32 beat Agenus' score of 0.18 indicating that Fortress Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 4 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Neutral Fortress Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Fortress Biotech (FBIO) Competitors

$3.30 0.00 (0.00%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$3.36 +0.07 (+1.97%)

As of 08:39 AM Eastern

Compare

FBIO vs. VSTM, VNDA, SABS, CDXS, and AGEN

Should you buy Fortress Biotech stock or one of its competitors? MarketBeat compares Fortress Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fortress Biotech include Verastem (VSTM), Vanda Pharmaceuticals (VNDA), SAB Biotherapeutics (SABS), Codexis (CDXS), and Agenus (AGEN). These companies are all part of the "biotechnology" industry.

How does Fortress Biotech compare to Verastem?

Fortress Biotech (NASDAQ:FBIO) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

Fortress Biotech has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.73	$6.82M	$3.17	1.04
Verastem	$30.91M	15.27	-$209.47M	-$2.70	N/A

Fortress Biotech currently has a consensus target price of $17.00, indicating a potential upside of 415.15%. Verastem has a consensus target price of $14.40, indicating a potential upside of 168.16%. Given Fortress Biotech's higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by insiders. Comparatively, 1.9% of Verastem shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Fortress Biotech has a net margin of 193.12% compared to Verastem's net margin of -391.17%. Fortress Biotech's return on equity of 109.66% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	193.12%	109.66%	45.56%
Verastem	-391.17%	-486.40%	-91.56%

In the previous week, Verastem had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 4 mentions for Verastem and 2 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 1.32 beat Verastem's score of 0.89 indicating that Fortress Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verastem	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortress Biotech has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, Verastem has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market.

Summary

Fortress Biotech beats Verastem on 12 of the 17 factors compared between the two stocks.

How does Fortress Biotech compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

Vanda Pharmaceuticals currently has a consensus price target of $14.30, indicating a potential upside of 138.33%. Fortress Biotech has a consensus price target of $17.00, indicating a potential upside of 415.15%. Given Fortress Biotech's higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Vanda Pharmaceuticals has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

Fortress Biotech has lower revenue, but higher earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.67	-$220.47M	-$4.05	N/A
Fortress Biotech	$63.26M	1.73	$6.82M	$3.17	1.04

In the previous week, Vanda Pharmaceuticals had 4 more articles in the media than Fortress Biotech. MarketBeat recorded 6 mentions for Vanda Pharmaceuticals and 2 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 1.32 beat Vanda Pharmaceuticals' score of 0.74 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortress Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortress Biotech has a net margin of 193.12% compared to Vanda Pharmaceuticals' net margin of -109.99%. Fortress Biotech's return on equity of 109.66% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%
Fortress Biotech	193.12%	109.66%	45.56%

Summary

Fortress Biotech beats Vanda Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Fortress Biotech compare to SAB Biotherapeutics?

SAB Biotherapeutics (NASDAQ:SABS) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

SAB Biotherapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

In the previous week, SAB Biotherapeutics had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 3 mentions for SAB Biotherapeutics and 2 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 1.32 beat SAB Biotherapeutics' score of 0.70 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortress Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 7.4% of SAB Biotherapeutics shares are owned by insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Fortress Biotech has a net margin of 193.12% compared to SAB Biotherapeutics' net margin of 0.00%. Fortress Biotech's return on equity of 109.66% beat SAB Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-0.29%	-0.25%
Fortress Biotech	193.12%	109.66%	45.56%

SAB Biotherapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 221.72%. Fortress Biotech has a consensus target price of $17.00, suggesting a potential upside of 415.15%. Given Fortress Biotech's higher possible upside, analysts plainly believe Fortress Biotech is more favorable than SAB Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

SAB Biotherapeutics has higher earnings, but lower revenue than Fortress Biotech. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	216.06	$13.27M	-$2.11	N/A
Fortress Biotech	$63.26M	1.73	$6.82M	$3.17	1.04

Summary

Fortress Biotech beats SAB Biotherapeutics on 11 of the 16 factors compared between the two stocks.

How does Fortress Biotech compare to Codexis?

Codexis (NASDAQ:CDXS) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

Fortress Biotech has lower revenue, but higher earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	2.91	-$43.97M	-$0.37	N/A
Fortress Biotech	$63.26M	1.73	$6.82M	$3.17	1.04

Codexis has a beta of 2.5, meaning that its stock price is 150% more volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market.

Fortress Biotech has a net margin of 193.12% compared to Codexis' net margin of -40.97%. Fortress Biotech's return on equity of 109.66% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-40.97%	-68.09%	-23.72%
Fortress Biotech	193.12%	109.66%	45.56%

Codexis presently has a consensus target price of $5.00, suggesting a potential upside of 122.22%. Fortress Biotech has a consensus target price of $17.00, suggesting a potential upside of 415.15%. Given Fortress Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Fortress Biotech is more favorable than Codexis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Codexis and Codexis both had 2 articles in the media. Fortress Biotech's average media sentiment score of 1.32 beat Codexis' score of 0.93 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortress Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.5% of Codexis shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 3.5% of Codexis shares are held by company insiders. Comparatively, 28.5% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Fortress Biotech beats Codexis on 12 of the 15 factors compared between the two stocks.

How does Fortress Biotech compare to Agenus?

Agenus (NASDAQ:AGEN) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Fortress Biotech has lower revenue, but higher earnings than Agenus. Fortress Biotech is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	2.24	$120K	$1.59	3.87
Fortress Biotech	$63.26M	1.73	$6.82M	$3.17	1.04

Fortress Biotech has a net margin of 193.12% compared to Agenus' net margin of 50.49%. Fortress Biotech's return on equity of 109.66% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	50.49%	-31.66%	42.71%
Fortress Biotech	193.12%	109.66%	45.56%

In the previous week, Agenus had 22 more articles in the media than Fortress Biotech. MarketBeat recorded 24 mentions for Agenus and 2 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 1.32 beat Agenus' score of 0.18 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	4 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Neutral
Fortress Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agenus has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market.

Agenus currently has a consensus target price of $30.00, indicating a potential upside of 387.80%. Fortress Biotech has a consensus target price of $17.00, indicating a potential upside of 415.15%. Given Fortress Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Agenus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

61.5% of Agenus shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 6.5% of Agenus shares are owned by insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Fortress Biotech beats Agenus on 11 of the 16 factors compared between the two stocks.

Get Fortress Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBIO vs. The Competition

Export

Metric	Fortress Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$109.62M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	1.04	20.85	27.11	24.26
Price / Sales	1.73	314.01	589.18	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	1.65	8.49	10.73	6.29
Net Income	$6.82M	$23.83M	$3.58B	$330.66M
7 Day Performance	10.37%	-3.56%	-2.11%	-1.35%
1 Month Performance	19.13%	6.31%	3.27%	-0.64%
1 Year Performance	68.37%	48.30%	26.32%	19.08%

Fortress Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBIO Fortress Biotech	2.8304 of 5 stars	$3.30 flat	$17.00 +415.2%	+74.6%	$109.62M	$63.26M	1.04	170	Positive News
VSTM Verastem	3.2678 of 5 stars	$4.46 -0.9%	$14.60 +227.4%	+14.7%	$395.43M	$30.91M	N/A	50
VNDA Vanda Pharmaceuticals	2.3714 of 5 stars	$6.23 +0.3%	$14.30 +129.5%	+26.6%	$373.44M	$216.10M	N/A	290
SABS SAB Biotherapeutics	2.8976 of 5 stars	$3.92 flat	$12.00 +206.1%	+43.5%	$299.74M	$1.32M	N/A	140
CDXS Codexis	3.042 of 5 stars	$2.66 +7.7%	$5.00 +88.0%	-24.7%	$224.51M	$70.39M	N/A	250

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBIO) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fortress Biotech (FBIO) Competitors

FBIO vs. VSTM, VNDA, SABS, CDXS, and AGEN

How does Fortress Biotech compare to Verastem?

Summary

How does Fortress Biotech compare to Vanda Pharmaceuticals?

Summary

How does Fortress Biotech compare to SAB Biotherapeutics?

Summary

How does Fortress Biotech compare to Codexis?

Summary

How does Fortress Biotech compare to Agenus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO vs. The Competition

Fortress Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fortress Biotech (FBIO) Competitors

FBIO vs. VSTM, VNDA, SABS, CDXS, and AGEN

How does Fortress Biotech compare to Verastem?

Which has preferable earnings & valuation, FBIO or VSTM?

Do analysts prefer FBIO or VSTM?

Do institutionals and insiders have more ownership in FBIO or VSTM?

Is FBIO or VSTM more profitable?

Does the media refer more to FBIO or VSTM?

Which has more volatility and risk, FBIO or VSTM?

Summary

How does Fortress Biotech compare to Vanda Pharmaceuticals?

Do analysts recommend VNDA or FBIO?

Do institutionals and insiders believe in VNDA or FBIO?

Which has more volatility & risk, VNDA or FBIO?

Which has stronger valuation and earnings, VNDA or FBIO?

Does the media prefer VNDA or FBIO?

Is VNDA or FBIO more profitable?

Summary

How does Fortress Biotech compare to SAB Biotherapeutics?

Which has more risk and volatility, SABS or FBIO?

Does the media prefer SABS or FBIO?

Do institutionals and insiders hold more shares of SABS or FBIO?

Is SABS or FBIO more profitable?

Do analysts rate SABS or FBIO?

Which has higher valuation & earnings, SABS or FBIO?

Summary

How does Fortress Biotech compare to Codexis?

Which has stronger valuation and earnings, CDXS or FBIO?

Which has more risk & volatility, CDXS or FBIO?

Is CDXS or FBIO more profitable?

Do analysts rate CDXS or FBIO?

Does the media prefer CDXS or FBIO?

Do institutionals & insiders have more ownership in CDXS or FBIO?

Summary

How does Fortress Biotech compare to Agenus?

Which has preferable valuation & earnings, AGEN or FBIO?

Is AGEN or FBIO more profitable?

Does the media favor AGEN or FBIO?

Which has more risk & volatility, AGEN or FBIO?

Do analysts prefer AGEN or FBIO?

Do institutionals and insiders hold more shares of AGEN or FBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO vs. The Competition

Fortress Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools